본문으로 건너뛰기
← 뒤로

Ga-pentixafor PET/CT shows better diagnostic performance than F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature.

Frontiers in oncology 2026 Vol.16() p. 1699568

Wu D, Hua R, Mao Z, Hu Y, Zhang J, Tian C, Zheng L, Zhang X, Bian Y

📝 환자 설명용 한 줄

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is an indolent B-cell lymphoma for which current imaging modalities offer limited diagnostic value.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Wu D, Hua R, et al. (2026). Ga-pentixafor PET/CT shows better diagnostic performance than F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature.. Frontiers in oncology, 16, 1699568. https://doi.org/10.3389/fonc.2026.1699568
MLA Wu D, et al.. "Ga-pentixafor PET/CT shows better diagnostic performance than F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature.." Frontiers in oncology, vol. 16, 2026, pp. 1699568.
PMID 42003974

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is an indolent B-cell lymphoma for which current imaging modalities offer limited diagnostic value. This article reports a comparison of the imaging features of F-FDG and Ga-pentixafor in this disease and reviews the relevant literature. A 60-year-old woman presented with a 6-month history of fever and scattered systemic lymphadenopathy. The patient underwent both F-FDG and Ga-pentixafor PET/CT imaging within a 2-day period. Ga-pentixafor PET/CT identified significantly increased metabolic activity in enlarged lymph nodes, the spleen, and bone marrow. Immunohistochemical staining demonstrated a phenotypic profile positive for CD5, CD20, and CD23; showed focal positivity for cyclin D1; and was negative for CD10, BCL-6, and SOX11, findings consistent with the diagnosis of CLL/SLL. Compared with F-FDG, Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with F-FDG PET/CT.

같은 제1저자의 인용 많은 논문 (5)